4 results
This is a follow-up (FU) study for subjects who completed Study ALX0681-C301 (HERCULES) according to the protocol (i.e., completed the Final [28 day] FU visit). Subjects who completed Study ALX0681-C301 will be given the option to participate in…
Currently, caplacizumab is being developed for treatment of acquired thrombotic thrombocytopenic purpura (TTP). TTP is a rare and potentially life-threatening thrombotic microangiopathy, in which accumulation of ULvWF multimers leads to an increased…
To assess the feasibility and safety of intraoperative dual-modality imaging in patients with renal cell carcinoma with Indium-111-DOTA-girentuximab-IRDye800CW. Secondary objectives are to assess how intraoperative fluorescence imaging results…
Primary objectives- A multicenter, open label non-randomized phase I/II dose escalation study with extension cohort to determine the safety, tolerability and immunogenicity of the therapeutic LRPAP1 synthetic long peptide ( LRPAP7-30V-SLP) vaccine (…